134 related articles for article (PubMed ID: 34109743)
1. Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents.
Fujii S; Kikuchi E; Suzuyama H; Watanabe Y; Ishigami-Yuasa M; Masuno H; Mori T; Isobe K; Uchida S; Kagechika H
ChemMedChem; 2021 Sep; 16(18):2817-2822. PubMed ID: 34109743
[TBL] [Abstract][Full Text] [Related]
2. Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling.
Fujii S; Kikuchi E; Watanabe Y; Suzuyama H; Ishigami-Yuasa M; Mori T; Isobe K; Uchida S; Kagechika H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127408. PubMed ID: 32738993
[TBL] [Abstract][Full Text] [Related]
3. Development of WNK signaling inhibitors as a new class of antihypertensive drugs.
Ishigami-Yuasa M; Watanabe Y; Mori T; Masuno H; Fujii S; Kikuchi E; Uchida S; Kagechika H
Bioorg Med Chem; 2017 Jul; 25(14):3845-3852. PubMed ID: 28566208
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters.
Kikuchi E; Mori T; Zeniya M; Isobe K; Ishigami-Yuasa M; Fujii S; Kagechika H; Ishihara T; Mizushima T; Sasaki S; Sohara E; Rai T; Uchida S
J Am Soc Nephrol; 2015 Jul; 26(7):1525-36. PubMed ID: 25377078
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
Nishida H; Sohara E; Nomura N; Chiga M; Alessi DR; Rai T; Sasaki S; Uchida S
Hypertension; 2012 Oct; 60(4):981-90. PubMed ID: 22949526
[TBL] [Abstract][Full Text] [Related]
6. WNK bodies cluster WNK4 and SPAK/OSR1 to promote NCC activation in hypokalemia.
Thomson MN; Cuevas CA; Bewarder TM; Dittmayer C; Miller LN; Si J; Cornelius RJ; Su XT; Yang CL; McCormick JA; Hadchouel J; Ellison DH; Bachmann S; Mutig K
Am J Physiol Renal Physiol; 2020 Jan; 318(1):F216-F228. PubMed ID: 31736353
[TBL] [Abstract][Full Text] [Related]
7. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy.
Mori T; Kikuchi E; Watanabe Y; Fujii S; Ishigami-Yuasa M; Kagechika H; Sohara E; Rai T; Sasaki S; Uchida S
Biochem J; 2013 Nov; 455(3):339-45. PubMed ID: 23981180
[TBL] [Abstract][Full Text] [Related]
8. WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension.
Brown A; Meor Azlan NF; Wu Z; Zhang J
Acta Pharmacol Sin; 2021 Apr; 42(4):508-517. PubMed ID: 32724175
[TBL] [Abstract][Full Text] [Related]
9. The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases.
AlAmri MA; Kadri H; Alderwick LJ; Jeeves M; Mehellou Y
Chembiochem; 2018 Oct; 19(19):2072-2080. PubMed ID: 29999233
[TBL] [Abstract][Full Text] [Related]
10. SPAK and WNK kinases: a new target for blood pressure treatment?
Glover M; O'shaughnessy KM
Curr Opin Nephrol Hypertens; 2011 Jan; 20(1):16-22. PubMed ID: 21088576
[TBL] [Abstract][Full Text] [Related]
11. SPAK deficiency corrects pseudohypoaldosteronism II caused by WNK4 mutation.
Chu PY; Cheng CJ; Wu YC; Fang YW; Chau T; Uchida S; Sasaki S; Yang SS; Lin SH
PLoS One; 2013; 8(9):e72969. PubMed ID: 24039833
[TBL] [Abstract][Full Text] [Related]
12. [WNK-SPAK-SLC12A signal cascade is a new therapeutic target for hypertension].
Kikuchi E; Mori T; Uchida S
Nihon Rinsho; 2015 Sep; 73(9):1597-605. PubMed ID: 26394527
[TBL] [Abstract][Full Text] [Related]
13. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
[TBL] [Abstract][Full Text] [Related]
14. Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal Domains.
AlAmri MA; Kadri H; Alderwick LJ; Simpkins NS; Mehellou Y
ChemMedChem; 2017 May; 12(9):639-645. PubMed ID: 28371477
[TBL] [Abstract][Full Text] [Related]
15. Acute insulin stimulation induces phosphorylation of the Na-Cl cotransporter in cultured distal mpkDCT cells and mouse kidney.
Sohara E; Rai T; Yang SS; Ohta A; Naito S; Chiga M; Nomura N; Lin SH; Vandewalle A; Ohta E; Sasaki S; Uchida S
PLoS One; 2011; 6(8):e24277. PubMed ID: 21909387
[TBL] [Abstract][Full Text] [Related]
16. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1.
Moriguchi T; Urushiyama S; Hisamoto N; Iemura S; Uchida S; Natsume T; Matsumoto K; Shibuya H
J Biol Chem; 2005 Dec; 280(52):42685-93. PubMed ID: 16263722
[TBL] [Abstract][Full Text] [Related]
17. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.
Thastrup JO; Rafiqi FH; Vitari AC; Pozo-Guisado E; Deak M; Mehellou Y; Alessi DR
Biochem J; 2012 Jan; 441(1):325-37. PubMed ID: 22032326
[TBL] [Abstract][Full Text] [Related]
18. SPAK and OSR1 play essential roles in potassium homeostasis through actions on the distal convoluted tubule.
Ferdaus MZ; Barber KW; López-Cayuqueo KI; Terker AS; Argaiz ER; Gassaway BM; Chambrey R; Gamba G; Rinehart J; McCormick JA
J Physiol; 2016 Sep; 594(17):4945-66. PubMed ID: 27068441
[TBL] [Abstract][Full Text] [Related]
19. Perspective of future drugs targeting sterile 20/SPS1-related proline/alanine-rich kinase for blood pressure control.
Lin GM; Liu PY; Wu CF; Wang WB; Han CL
World J Cardiol; 2015 Jun; 7(6):306-10. PubMed ID: 26131334
[TBL] [Abstract][Full Text] [Related]
20. Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade.
Chiga M; Rafiqi FH; Alessi DR; Sohara E; Ohta A; Rai T; Sasaki S; Uchida S
J Cell Sci; 2011 May; 124(Pt 9):1391-5. PubMed ID: 21486947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
